Drug for contrast-enhanced ultrasound examination: new dimension in early diagnosis of angionephrosclerosis in patients with type 2 diabetes on non-alcoholic fatty liver disease background
https://doi.org/10.33667/2078-5631-2020-30-37-41
Abstract
Objective. To evaluate the diagnostic efficiency of the contrast-enhanced third-generation agent in the detection of angionephrosclerosis in patients with type 2 diabetes and non-alcoholic fatty liver disease background.
Materials and methods. 26 patients (9 men and 17 women; mean age 61.5 ± 4.3 years) with a confirmed diagnosis of type 2 diabetes mellitus and NAFLD were examined. All patients underwent complex diagnostics, including: quantitative ultrasound steatometry of the liver in the framework of combined elastography with visual and quantitative assessment of the attenuation coefficient of the ultrasonic wave; ultrasound examination of the kidneys in B-mode with vascular diagnostics in the Doppler mapping mode. Also, all patients underwent contrast-enhanced ultrasound examination of the kidneys with the contrast agent for the diagnosis of angionephrosclerosis.
Results. The method of CEUS of the kidneys with patients with type 2 diabetes and NAFLD has sensitivity of 92.7 %, and accuracy of 90.4 %. Color Doppler mode has sensitivity of 66.5–81.4 %, and accuracy of 58.4–73.6 %.
Conclusion. The ultrasound contrast agent may be used in the early diagnosis of angionephrosclerosis in patients with type 2 diabetes and NAFLD as a non-alternative imaging method with no radiation exposure and no nephrotoxicity.
About the Authors
A. V. Borsukov
Smolensk State Medical University
Russian Federation
Smolensk
Russian Federation
Smolensk
O. A. Gorbatenko
Smolensk State Medical University
Russian Federation
Smolensk
Russian Federation
Smolensk
D. Yu. Venidiktova
Smolensk State Medical University
Russian Federation
Smolensk
Russian Federation
Smolensk
I. Z. Pulatova
Tashkent Institute for Advanced Medical Studies
Uzbekistan
Tashkent
Uzbekistan
Tashkent
References
1. International Diabetes Federation, 2019. Режим доступа: https://www.idf.org/
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 9-й выпуск (дополненный). М.; 2019. С. 104–109.
3. Практические рекомендации KDIGO по диагностике, профилактике и лечению минеральных и костных нарушений при хронической болезни почек (ХБП-МКН). Краткое изложение рекомендаций. Нефрология 2011; 15(1): С. 88–95.
4. Zobair M., Aaron B. Koenig, Dinan Abdelatif, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease – Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 2016, No. 64 (1), P. 73–84.
5. Борсуков А. В., Венидиктова Д. Ю. Ультразвуковая диагностика стеатоза печени: разработка новой методики количественной оценки патологического процесса. // Медицинский алфавит. 2017. 19. С. 47–51.
6. Тиханкова А. В., Борсуков А. В., Буеверов А. О., и др. Усовершенствованная методика контрастно-усиленного ультразвукового исследования при хронических вирусных гепатитах. // Клиническая практика. 2019. Т. 10. № 1. C. 4–9. DOI: 10.17816/clinpract1014–9.
7. Solovev Ya.A., Mitina L. A., Mitkova M. D. Contrast-enhanced ultrasound (CEUS) in differential diagnosis of benign and malignant renal tumors. // Ultrasound and Functional Diagnostics. 2018. No. 4. P. 46–64.
8. Sidhu P. S., Cantisani V., Dietrich C. F., Gilja O. H., Saftoiu A., Bartels E., Bertolotto M., Calliada F., Clevert D. A., Cosgrove D., Deganello A., D’Onofrio M., Drudi F. M., Freeman S., Harvey C., Jenssen C., Jung E. M., Klauser A. S., Lassau N., Meloni M. F., Leen E., Nicolau C., Nolsoe C., Piscaglia F., Prada F., Prosch H., Radzina M., Savelli L., Weskott H. P., Wijkstra H. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version). // Ultraschall Med. 2018. V. 39. No. 2. P. e2–e44. DOI: 10.1055/a‑0586–1107.
9. Claudon M., Dietrich C. F., Choi B. I., Cosgrove D. O., Kudo M., Nolsoe C. P., Piscaglia F., Wilson S. R., Barr R. G., Chammas M. C., Chaubal N. G., Chen M. H., Clevert D. A., Correas J. M., Ding H., Forsberg F., Fowlkes J. B., Gibson R. N., Goldberg B. B., Lassau N., Leen E. L., Mattrey R. F., Moriyasu F., Solbiati L., Weskott H. P., Xu H. X. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. // Ultraschall Med. 2013. V. 34. No. 1. P. 11–29. DOI: 10.1055/s‑0032–1325499.
10. Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated
11. retinopathy in type 2 diabetic patients. Diabetologia, 2008, No. 51, P. 444–450.
12. Targher G., Chonchol M., Bertolini L., et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol., 2010, No. 5, P. 2166–2171.
13. Sit D., Kadiroglu A. K., Kayabasi H., Yilmaz M. E. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv. Ther., 2000, No. 23 (6), Р. 988–998.
14. Козлова Е. Ю. Особенности структурно-функционального состояния почек у детей подросткового возраста с ожирением: дис…канд. мед. наук:14.01.08. Смол. гос. мед. университет, Смоленск, 2018, 147 с.
15. Sidhu P. S., Cantisani V., Dietrich C. F., Gilja O. H., Saftoiu A., Bartels E., Bertolotto M., Calliada F., Clevert D. A., Cosgrove D., Deganello A., D’Onofrio M., Drudi F. M., Freeman S., Harvey C., Jenssen C., Jung E. M., Klauser A. S., Lassau N., Meloni M. F., Leen E., Nicolau C., Nolsoe C., Piscaglia F., Prada F., Prosch H., Radzina M., Savelli L., Weskott H. P., Wijkstra H. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version). // Ultraschall Med. 2018. V. 39. No. 2. P. e2–e44. DOI: 10.1055/a‑0586–1107.
16. Bertolotto M. Color Doppler sonographic appearance of renal perforating vessels in subjects with normal and impaired renal function [Text] / M. Bertolotto, E. Quaia, G. Galli et al. // Journal of Clinical Ultrasound. 2000. Vol. 28, No. 6. P. 267–276.
17. James А. Sheiman, Патофизиология почки. / Пер. с англ. М.: Издательство БИНОМ, С. 2019, 192.
Review
For citations:
Borsukov A.V., Gorbatenko O.A., Venidiktova D.Yu., Pulatova I.Z. Drug for contrast-enhanced ultrasound examination: new dimension in early diagnosis of angionephrosclerosis in patients with type 2 diabetes on non-alcoholic fatty liver disease background. Medical alphabet. 2020;1(30):37-41. (In Russ.) https://doi.org/10.33667/2078-5631-2020-30-37-41
Views:
431
Email this article 